Member Info for Marty130

Billions....They will carry out 2 for 1 consolidatation should this hit 80p.

As of late October 2025, major shareholders of Renalytix include several investment firms, institutions, and certain directors

. Recent regulatory filings indicate some changes in the holdings of significant institutional investors.

Major institutional shareholders

UBS Group AG: Recently crossed the 8% voting rights threshold as of October 22, 2025, holding 8.002628% through its subsidiary, UBS AG.

Jefferson River Capital LLC: Holds 9.3% of ordinary shares, with 30,755,501 shares.

Ruffer LLP: Owns 8.6% of ordinary shares, with 28,500,000 shares.

Polar Capital: Holds 8.2% of ordinary shares, with 27,246,197 shares.

Unicorn Asset Management Limited: Possesses 5.7% of ordinary shares, with 18,955,777 shares.

Heights Capital Management, Inc.: Filed a notification in mid-October 2025, disclosing a holding of 9.874%.

Pentwater Capital Management LP: Last filed in early October 2025, with a holding of 7.816294%.

The Mount Sinai Hospital: Owns 11.34% of equities, totaling 37,550,977.

Director and related holdings

Christopher Mills: As Chairman, has a 4.4% stake through entities he is involved with, including North Atlantic Smaller Companies Investment Trust PLC and Harwood Capital LLP.

James McCullough: The CEO, holds 1.0% through his family trust.

The Icahn School of Medicine at Mount Sinai: Has an equity ownership in Renalytix, a result of the technology development for KidneyIntelX

Agreed.. Which is why analysts state the below.

The average 12-month price target for Aptamer Group PLC (APTA) is around 183.60 GBX, with analyst forecasts ranging from 181.80 GBX to 189.00 GBX. This consensus target price represents a significant increase from its last closing price of around 0.87 GBX. However, some analysts have also noted potential negative signals for the stock, so it's important to consider multiple perspectives.

UBS back again, this time up 1% to 8%...

I did.

You do the maths.

A chap I know bought 3 million shares in this company..He has been very successful at picking out these penny stock companies. And I'm talking millions. He bought two million FTC share at 7p, and recently sold at 150p..

Aptamer's business model is designed to generate revenue through both fee-for-service work and licensing agreements, which include upfront payments, milestone payments, and royalties. The success of the Unilever project could lead to significant future income through licensing.

What the heck is UBS up to..

Get back to you with that in the morning.

From research.

There is a lot happening behind the scenes.. SP won't move much until they announce any major deals.

Strange that a bidder is not forthcoming. Perhapse it because the bid is coming from within.

I can't find any evidence to support a takeover

They are upto their usual tricks again..

Of Trades 311

Vol Sold 4,323,043

Vol Bought 8,009,854

52 Week High 12.50

52 Week High Date 07-Jan-2025

52 Week Low 5.75

52 Week Low Date 27-Aug-20

Up 3.8%.

Heights Capital Management (HCM) has increased its stake in Renalytix PLC to 9.874% after converting senior convertible bonds, which also boosted Renalytix's balance sheet by approximately \(\$4\) million. The conversion, which resulted in the issuance of over 31 million new shares at a price of \(9.5\) pence each, improves Renalytix's debt-to-equity ratio and reduces its interest payments

I don't please tell!

Ok